Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Danaher's Strategic Abcam Deal Boosts Growth at a Reasonable Price: Analyst

Author: Vandana Singh | August 29, 2023 03:09pm

Monday, Danaher Corporation (NYSE:DHR) had agreed to acquire Abcam plc (NASDAQ:ABCM) for $24.00 per share in cash, or a total enterprise value of ~$5.7 billion, including assumed indebtedness and net of acquired cash.

The transaction is anticipated to close in mid-2024 and will be funded using cash on hand and proceeds from the issuance of commercial paper.

William Blair analysts Matt Larew, Sam Martin, and Madeline Mollman say that the alignment between Abcam and Danaher appears to be well-suited in terms of financial considerations, promoting growth and bolstering margins. 

This acquisition offers Danaher an avenue to penetrate the proteomics reagents market, a domain where key players such as Thermo Fisher Scientific Inc (NYSE:TMO) and Merck Millipore have already established strong positions.

Danaher's strategic move places it at the forefront of the antibodies sector, especially within research-use-only (RUO) antibodies, where Abcam is the undisputed leader, the analyst notes.

The analyst perceives the Abcam acquisition as a step that won't impede other potential mergers and acquisitions in Danaher's trajectory.

The timing is also a positive given that Abcam is emerging from a multiyear investment period, and profitability in recent periods has begun to improve meaningfully.

Price Action: DHR shares are up 0.91% at $263.89 on the last check Tuesday.

Posted In: ABCM DHR TMO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist